ClinicalTrials.gg
RecruitingNCT06257693Updated Aug 11, 2026

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

A Phase 1 interventional study of enzalutamide in Prostate Adenocarcinoma, sponsored by Alessa Therapeutics Inc.. Recruiting at 10 sites in United States. Open to male participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Alessa Therapeutics Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
21 Years and older
Sex
Male
01

Study summary

The study is to assess whether the Enolen is safe and delivers anti-androgen medication locally in patients that are planning for radical prostatectomy.

Read the detailed description

This study is a multi-center, open-label feasibility study. Approximately 45 participants planning for radical prostatectomy will be recruited to assess the safety and patient tolerance of Enolen for the localized delivery of enzalutamide into the prostate.

At baseline, patients will undergo multiparametric MRI of the prostate. Study participants will have placement of the drug eluting Enolen implants followed by a standard of care prostatectomy 6-12 weeks or 4-12 months post-implant procedure.

Twenty participants in Cohort A receive up to 16 implants and have a prostatectomy planned between weeks 6 and 12 post-implant procedure.

Twelve participants in Cohort B receive 16 implants and have a prostatectomy planned between weeks 6 and 12 post-implant procedure.

Twelve participants in Cohort C receive 16 implants and have a prostatectomy planned between months 4 and 12 post-implant procedure. If the participant is unwilling to undergo the prostatectomy by 12 months, they must agree to close monitoring with imaging by MRI every three months and biopsies, as indicated, for up to 24 months post-implant procedure.

Study participants are followed for 2-6 weeks post-prostatectomy.

Participants will be followed for an additional 6-12 weeks post surgery. Clinical labs and correlative sample collection and patient quality of life questionnaires will be administered at follow-up visits.

02

Conditions studied

  • Prostate Adenocarcinoma
03

In context

Lead sponsor

Alessa Therapeutics Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age at least 21 years old
  2. confirmed adenocarcinoma of the prostate
  3. Study participant qualified and planning for radical prostatectomy
  4. At least 1 prostate lesion measurable by MRI greater or equal to 0.5 cm
  5. Cohort A and Cohort B: Gleason score 3+4 or higher Cohort C: Gleason score 3+3 with high risk features or 3+4
  6. Study participant must be willing to undergo post-treatment imaging by MRI
  7. Participants must be able to understand and sign the form
  8. performance status 0 or 1
  9. Adequate organ function, including (ANC) ≥1000 cells/μL, ≥9 g/dL, ≥100,000 cells/μL, estimated ≥50 mL/min, \<1.5x (\< 3x ULN for documented Gilbert's syndrome)
  10. (AST), alanine aminotransferase (ALT) and Alkaline phosphatase \<2.5x ULN
  11. The effects of Enolen on the developing human fetus are unknown. For this reason and because other therapeutic agents used in this trial are known to be teratogenic, men must agree to use a highly effective form of or abstinence at the time of study entry and continuing through three months after radical prostatectomy/implant removal. Highly effective forms of contraception include:

Vasectomy Condom with spermicide

Partner use of one of the following methods:

>1 year or age >55y Bilateral tubal ligation Intrauterine devices (IUDs) Hormonal implants (Implanon, Nexplanon, etc.) Combination oral contraceptives Progestin-only injections (Depo-Provera) Hormonal patches Vaginal Ring Should a woman become pregnant or suspect she is pregnant while her partner is participating in this study, the treating physician should be informed immediately.

Exclusion criteria

Exclusion Criteria:

  1. Prior radiotherapy or surgery for prostate cancer
  2. Ongoing hormonal therapy for prostate cancer or hormone therapy \<3 months prior to the start of treatment
  3. Prior prostate procedures such as transurethral resection of the prostate, transurethral microwave thermotherapy of the prostate, high-intensity focused ultrasound or minimally invasive Benign Prostate Hyperplasia (BPH) procedure
  4. Study participant unwilling or unable to undergo MRI, including participants with to MRI, such as cardiac pacemakers, non-compatible intracranial vascular clips, etc.
  5. Metallic hip implant or any other metallic implant or device that distorts the quality of prostatic MR images.
  6. Study participants who, because of age, general medical or psychiatric condition, or physiologic status cannot give valid .
  7. Presence of any disease.
  8. No evidence of extracapsular extension of disease.
  9. Study participants, who in the opinion of the treating clinician, would be at increased risk of urinary retention due to a transperineal procedure such as the Enolen implant.
  10. History of prostate infection within 2 years.
  11. No intercurrent medical condition or circumstances that would preclude prostatectomy.
  12. History of bleeding diathesis or currently on anti-coagulation therapy that cannot be safely discontinued for implant procedure.
  13. Any condition that, in the opinion of the Principal Investigator, which would impair the participant's ability to comply with study procedures and undergo prostatectomy.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Enolen (tm)

    Enolen (tm) implants containing enzalutamide

    Drug: enzalutamide

Interventions

  • Localized single delivery of the Enolen implant (polymer + enzalutamide) with planned radical prostatectomy

    Also known as: Radical prostatectomy

06

What researchers measure

Primary outcomes

  1. To assess the adverse events associated with the Enolen implant

    Using Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v.5.0).

    Time frame: up to 12 months

  2. Measurement of Pharmacokinetics Profile

    Enzalutamide plasma (ng/ml), tissue levels (ng/gm) and optional seminal fluid levels (ng/ml)

    Time frame: up to 12 months

Secondary outcomes

  1. MRI changes

    Prostate and tumor volume changes (mm3)

    Time frame: up to 12 months post Enolen implantation

  2. Changes in Prostate-specific antigen (PSA)

    Measurements of the amount of PSA in the blood (ng/ml) at baseline through 6-12 weeks post radical prostatectomy

    Time frame: 6 to 12 weeks post radical prostatectomy

  3. Changes in Testosterone

    Measurements of testosterone levels in the blood (ng/dl) from baseline to radical prostatectomy

    Time frame: 6 to 12 weeks post Enolen implantation

07

Study locations

10 of 10 sites recruiting
  • Urology Associates of Central California
    Fresno, California 93720, United States
    Recruiting
  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center
    San Francisco, California 94158, United States
    Recruiting
  • Northwestern University
    Chicago, Illinois 60611, United States
    Recruiting
  • Mary Bird Cancer Center
    Metairie, Louisiana 70002, United States
    Recruiting
  • Johns Hopkins University School of Medicine
    Baltimore, Maryland 21287, United States
    Recruiting
    • Rana Harb · Contactrharb1@jhmi.edu · 410-502-2276
    • George Metri · Contactgmetri1@jh.edu · 410-502-2276
    • Arvin George, MD · Principal investigator
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • Katie Evans, RN · Contactkatie.evans@nih.gov · 240-401-2157
    • Peter Pinto, MD · Principal investigator
  • VA Portland Health Care System
    Portland, Oregon 97239, United States
    Recruiting
    • Laura Onstad · Contactlaura.onstad@va.gov · 503-721-1060
    • Ryan Kopp, MD · Principal investigator
  • Atlantic Urology Specialists
    Myrtle Beach, South Carolina 29572, United States
    Recruiting
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
    Recruiting
    • Genelle Gaudinez · Contactgaudinezg@vcu.edu · 804-628-6430
    • Alexander Kenigsberg, MD · Principal investigator
  • Aurora Urology
    Milwaukee, Wisconsin 53215, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Alessa Therapeutics will allow NCI to share data, including genomic data, on this project.

Supporting information: Study protocol, Informed consent form, Clinical study report

Time frame: Data is shared after the completion of the study.

Access criteria: Data will be provided by the sponsor/Alessa Therapeutics to the NIH for sharing per the NIH Data Managment and Sharing Policy

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Dec 2028, 54 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2023
First posted
Feb 14, 2024
StartActual
Jun 21, 2024
Primary completionEst.
Dec 30, 2028
CompletionEst.
Dec 30, 2028
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06257693
Lead sponsor
Alessa Therapeutics Inc.
Responsible party
Sponsor
First posted
Feb 14, 2024
Start date
Jun 21, 2024
Primary completion
Dec 30, 2028 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Aug 11, 2026

Study contacts

Bonnie Wettersten, MS
Contact
bonnie.wettersten@alessatherapeutics.com
847-644-9818
Pamela Munster, MD
Contact
pamela.munster@alessatherapeutics.com
415-216-6099
Peter Pinto, MD
principal investigator · National Cancer Institute (NCI)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion